Using real world evidence to characterise a cohort of metastatic uveal melanoma patients in England
Rapid testing and treatment for sexually transmitted infections improve patient care and yield public health benefits
Modelling how point-of-care tests can enable personalised treatment for resistant gonorrhoea infections
Point-of-care tests for infectious diseases: Barriers to implementation across three London teaching hospitals
Cervical screening and HPV testing: Opportunities for rapid tests
We explored the use of a rapid, on-demand human papillomavirus (HPV) test. Interviews with UK experts revealed that a co-located, on-demand HPV test following cytology could reduce the time to cervical screening results by up to a week, with a near-patient primary HPV test followed by cytology triage could radically change the testing paradigm. A follow-up tool we built in Excel was used to understand cervical screening burden and HPV testing across Europe.
How can European countries improve cervical cancer prevention for women?
Exploring the value of a rapid, on-demand test for the detection of human papillomavirus
Estimating the true costs of splitting HIV antiretroviral drugs
There is a temptation to switch to cheaper generic antiretroviral drugs compared to fixed-dose combination therapy for HIV patients in the interests of cost savings. However, in our analysis we found that there were no costs saved when including all patient care including drugs, additional clinic visits and monitoring. We also found that switching may cause confusion for some patients, risking loss of adherence. This evidence can help commissioners make better policy decisions about drug provision.
Understanding Idiopathic Pulmonary Fibrosis patient care delivery and costs
We explored patient pathways for the diagnosis, management and monitoring of idiopathic pulmonary fibrosis (IPF) across England, based on NICE pathways, and interviews with healthcare staff from 14 hospital trusts. Data were used in our in-house tool to estimate the cost of pathways, compared to tariff reimbursement. We found large variation across England in how services for IPF patients are delivered, variation compared to the NICE pathway, and costs >40% more than what is currently reimbursed.
The benefits and cost-savings of a new point-of-care test for chlamydia and gonorrhoea
We developed an understanding of how sexual health clinics in England could use a rapid point of care test for two common sexually transmitted infections. We defined the current patient care pathways and found that the pathways could be streamlined and costs of care reduced by using point-of-care tests. The economic model developed by Aquarius Population Health showed that the test could deliver £10 million in cost savings, and give far more effective management of chlamydia and gonorrhoea at a population level.